Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.
2.

Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung.

Woodworth JS, Cohen SB, Moguche AO, Plumlee CR, Agger EM, Urdahl KB, Andersen P.

Mucosal Immunol. 2017 Mar;10(2):555-564. doi: 10.1038/mi.2016.70.

3.

Designing and Construction of a DNA Vaccine Encoding Tb10.4 Gene of Mycobacterium tuberculosis.

Rashidian S, Teimourpour R, Meshkat Z.

Iran J Pathol. 2016 Spring;11(2):112-9.

4.

Improving the Immunogenicity of the Mycobacterium bovis BCG Vaccine by Non-Genetic Bacterial Surface Decoration Using the Avidin-Biotin System.

Liao TY, Lau A, Joseph S, Hytönen V, Hmama Z.

PLoS One. 2015 Dec 30;10(12):e0145833. doi: 10.1371/journal.pone.0145833.

5.

The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans.

Mothé BR, Lindestam Arlehamn CS, Dow C, Dillon MB, Wiseman RW, Bohn P, Karl J, Golden NA, Gilpin T, Foreman TW, Rodgers MA, Mehra S, Scriba TJ, Flynn JL, Kaushal D, O'Connor DH, Sette A.

Tuberculosis (Edinb). 2015 Dec;95(6):722-35. doi: 10.1016/j.tube.2015.07.005.

6.

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG.

Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6.

7.

Multi-Stage Tuberculosis Subunit Vaccine Candidate LT69 Provides High Protection against Mycobacterium tuberculosis Infection in Mice.

Niu H, Peng J, Bai C, Liu X, Hu L, Luo Y, Wang B, Zhang Y, Chen J, Yu H, Xian Q, Zhu B.

PLoS One. 2015 Jun 22;10(6):e0130641. doi: 10.1371/journal.pone.0130641.

8.

A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation.

Aboutorabian S, Hakimi J, Boudet F, Montano S, Dookie A, Roque C, Ausar SF, Rahman N, Brookes RH.

Hum Vaccin Immunother. 2015;11(6):1449-55. doi: 10.1080/21645515.2015.1023970.

9.

Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.

Teng X, Tian M, Li J, Tan S, Yuan X, Yu Q, Jing Y, Zhang Z, Yue T, Zhou L, Fan X.

Hum Vaccin Immunother. 2015;11(6):1456-64. doi: 10.1080/21645515.2015.1037057.

10.

Aerosol immunisation for TB: matching route of vaccination to route of infection.

Manjaly Thomas ZR, McShane H.

Trans R Soc Trop Med Hyg. 2015 Mar;109(3):175-81. doi: 10.1093/trstmh/tru206. Review.

11.

Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Villarreal DO, Walters J, Laddy DJ, Yan J, Weiner DB.

Hum Vaccin Immunother. 2014;10(8):2188-98. doi: 10.4161/hv.29574.

12.

Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.

Orr MT, Ireton GC, Beebe EA, Huang PW, Reese VA, Argilla D, Coler RN, Reed SG.

J Immunol. 2014 Sep 15;193(6):2911-8. doi: 10.4049/jimmunol.1401103.

13.

Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.

Duthie MS, Coler RN, Laurance JD, Sampaio LH, Oliveira RM, Sousa AL, Stefani MM, Maeda Y, Matsuoka M, Makino M, Reed SG.

Infect Immun. 2014 Sep;82(9):3979-85. doi: 10.1128/IAI.02145-14.

14.

Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis.

Yuk JM, Jo EK.

Clin Exp Vaccine Res. 2014 Jul;3(2):155-67. doi: 10.7774/cevr.2014.3.2.155. Review.

15.

Novel vaccination strategies against tuberculosis.

Andersen P, Kaufmann SH.

Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a018523. doi: 10.1101/cshperspect.a018523. Review.

16.

Vaccine against tuberculosis: what's new?

Montagnani C, Chiappini E, Galli L, de Martino M.

BMC Infect Dis. 2014;14 Suppl 1:S2. doi: 10.1186/1471-2334-14-S1-S2. Review.

17.

Screening vaccine formulations for biological activity using fresh human whole blood.

Brookes RH, Hakimi J, Ha Y, Aboutorabian S, Ausar SF, Hasija M, Smith SG, Todryk SM, Dockrell HM, Rahman N.

Hum Vaccin Immunother. 2014;10(4):1129-35.

18.

ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.

Hoang T, Aagaard C, Dietrich J, Cassidy JP, Dolganov G, Schoolnik GK, Lundberg CV, Agger EM, Andersen P.

PLoS One. 2013 Dec 12;8(12):e80579. doi: 10.1371/journal.pone.0080579.

19.
20.

Optimizing Escherichia coli as a protein expression platform to produce Mycobacterium tuberculosis immunogenic proteins.

Piubelli L, Campa M, Temporini C, Binda E, Mangione F, Amicosante M, Terreni M, Marinelli F, Pollegioni L.

Microb Cell Fact. 2013 Nov 19;12:115. doi: 10.1186/1475-2859-12-115.

Supplemental Content

Support Center